MX2021012321A - Derivados del carbamoil-ciclohexano para tratar el trastorno del espectro autista. - Google Patents
Derivados del carbamoil-ciclohexano para tratar el trastorno del espectro autista.Info
- Publication number
- MX2021012321A MX2021012321A MX2021012321A MX2021012321A MX2021012321A MX 2021012321 A MX2021012321 A MX 2021012321A MX 2021012321 A MX2021012321 A MX 2021012321A MX 2021012321 A MX2021012321 A MX 2021012321A MX 2021012321 A MX2021012321 A MX 2021012321A
- Authority
- MX
- Mexico
- Prior art keywords
- disorder
- autism spectrum
- spectrum disorder
- derivatives
- autism
- Prior art date
Links
- 208000029560 autism spectrum disease Diseases 0.000 title abstract 4
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical class NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 title 1
- KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 abstract 3
- 201000007197 atypical autism Diseases 0.000 abstract 2
- 229960005123 cariprazine Drugs 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 208000036640 Asperger disease Diseases 0.000 abstract 1
- 201000006062 Asperger syndrome Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000006289 Rett Syndrome Diseases 0.000 abstract 1
- 208000024825 childhood disintegrative disease Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 230000001953 sensory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere al compuesto de trans-N-[4-[2-[4-(2,3-diclorofenil)piperazin-1-il]etil]ciclohexil ]-N',N'-dimetilurea (cariprazina), sus sales, análogos cercanos, derivados, composiciones farmacéuticas, metabolitos y combinaciones para usarse en el tratamiento de los síntomas del trastorno del espectro autista en general, y preferentemente el objeto de la presente invención es tratar uno o más síntomas del autismo. Además, se determinó también que la cariprazina, sus sales, análogos cercanos, derivados, composiciones farmacéuticas, metabolitos y combinaciones son adecuadas para el tratamiento de afecciones tales como el síndrome de Asperger, autismo atípico (también conocido como trastorno generalizado del desarrollo no especificado de otra manera, TGD NE), el síndrome de Rett, el trastorno desintegrativo de la infancia, el trastorno por el déficit de atención e hiperactividad (TDAH) y la disfunción de integración sensorial.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP1900121A HU231500B1 (hu) | 2019-04-10 | 2019-04-10 | Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére |
| PCT/IB2020/053382 WO2020208564A1 (en) | 2019-04-10 | 2020-04-09 | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021012321A true MX2021012321A (es) | 2021-11-12 |
Family
ID=89992883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012321A MX2021012321A (es) | 2019-04-10 | 2020-04-09 | Derivados del carbamoil-ciclohexano para tratar el trastorno del espectro autista. |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP3952872B1 (es) |
| JP (1) | JP2022527386A (es) |
| KR (1) | KR20210151162A (es) |
| CN (1) | CN113677345A (es) |
| AR (1) | AR118634A1 (es) |
| AU (1) | AU2020271363A1 (es) |
| BR (1) | BR112021019367A2 (es) |
| CL (1) | CL2021002632A1 (es) |
| DK (1) | DK3952872T3 (es) |
| EA (1) | EA202192717A1 (es) |
| ES (1) | ES2980780T3 (es) |
| FI (1) | FI3952872T3 (es) |
| GE (1) | GEP20237554B (es) |
| HR (1) | HRP20240772T1 (es) |
| HU (2) | HU231500B1 (es) |
| IL (1) | IL287076A (es) |
| LT (1) | LT3952872T (es) |
| MX (1) | MX2021012321A (es) |
| PL (1) | PL3952872T3 (es) |
| PT (1) | PT3952872T (es) |
| RS (1) | RS65530B1 (es) |
| SG (1) | SG11202110421YA (es) |
| SI (1) | SI3952872T1 (es) |
| TW (1) | TW202103701A (es) |
| UY (1) | UY38657A (es) |
| WO (1) | WO2020208564A1 (es) |
| ZA (1) | ZA202108429B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114588162B (zh) * | 2022-03-30 | 2023-10-27 | 中国人民解放军空军军医大学 | 拉莫三嗪治疗孤独症触觉异常的应用 |
| US11980603B2 (en) | 2022-06-11 | 2024-05-14 | AMS Therapeutics, LLC | Method of treating expressive language deficit in autistic humans |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227534B1 (en) | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
| EA017732B1 (ru) | 2007-05-11 | 2013-02-28 | Рихтер Гедеон Нирт. | Сольватная и кристаллическая формы гидрохлорида транс-1{4-[2-[4-(2,3-дихлорфенил)пиперазин-1-ил]этил]циклогексил}-3,3-диметилмочевины, способы их получения и их применение в фармацевтических композициях и способах лечения состояний, для которых необходима модуляция дофаминовых рецепторов |
| HU230748B1 (hu) | 2007-05-11 | 2018-02-28 | Richter Gedeon Nyrt | Új piperazin só és előállítási eljárása |
| HUP0700353A2 (en) | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
| EP2185155B1 (en) * | 2007-08-03 | 2017-10-04 | Richter Gedeon Nyrt. | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands |
| PL2317852T3 (pl) | 2008-07-16 | 2015-05-29 | Richter Gedeon Nyrt | Preparaty farmaceutyczne zawierające ligandy receptora dopaminy |
| US20110117214A1 (en) | 2009-11-16 | 2011-05-19 | Auspex Pharmaceuticals, Inc. | Cyclohexyl urea modulators of d2 receptors and/or d3 receptors |
| EP3079688B1 (en) | 2013-12-13 | 2017-11-22 | Pierre Fabre Medicament | A chromone derivative as a dopamine d3 receptor antagonist for its use in the treatment of autism spectrum disorder |
-
2019
- 2019-04-10 HU HUP1900121A patent/HU231500B1/hu unknown
-
2020
- 2020-03-11 TW TW109108018A patent/TW202103701A/zh unknown
- 2020-04-08 AR ARP200101001A patent/AR118634A1/es unknown
- 2020-04-09 DK DK20719737.7T patent/DK3952872T3/da active
- 2020-04-09 SI SI202030436T patent/SI3952872T1/sl unknown
- 2020-04-09 HU HUE20719737A patent/HUE066941T2/hu unknown
- 2020-04-09 LT LTEPPCT/IB2020/053382T patent/LT3952872T/lt unknown
- 2020-04-09 PL PL20719737.7T patent/PL3952872T3/pl unknown
- 2020-04-09 BR BR112021019367A patent/BR112021019367A2/pt unknown
- 2020-04-09 GE GEAP202015793A patent/GEP20237554B/en unknown
- 2020-04-09 EA EA202192717A patent/EA202192717A1/ru unknown
- 2020-04-09 SG SG11202110421YA patent/SG11202110421YA/en unknown
- 2020-04-09 HR HRP20240772TT patent/HRP20240772T1/hr unknown
- 2020-04-09 KR KR1020217036553A patent/KR20210151162A/ko active Search and Examination
- 2020-04-09 EP EP20719737.7A patent/EP3952872B1/en active Active
- 2020-04-09 FI FIEP20719737.7T patent/FI3952872T3/fi active
- 2020-04-09 CN CN202080027793.XA patent/CN113677345A/zh active Pending
- 2020-04-09 PT PT207197377T patent/PT3952872T/pt unknown
- 2020-04-09 RS RS20240573A patent/RS65530B1/sr unknown
- 2020-04-09 JP JP2021559605A patent/JP2022527386A/ja active Pending
- 2020-04-09 WO PCT/IB2020/053382 patent/WO2020208564A1/en active Application Filing
- 2020-04-09 AU AU2020271363A patent/AU2020271363A1/en active Pending
- 2020-04-09 ES ES20719737T patent/ES2980780T3/es active Active
- 2020-04-09 MX MX2021012321A patent/MX2021012321A/es unknown
- 2020-04-13 UY UY0001038657A patent/UY38657A/es unknown
-
2021
- 2021-10-07 IL IL287076A patent/IL287076A/en unknown
- 2021-10-08 CL CL2021002632A patent/CL2021002632A1/es unknown
- 2021-10-29 ZA ZA2021/08429A patent/ZA202108429B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY38657A (es) | 2020-10-30 |
| WO2020208564A1 (en) | 2020-10-15 |
| AR118634A1 (es) | 2021-10-20 |
| IL287076A (en) | 2021-12-01 |
| ES2980780T3 (es) | 2024-10-03 |
| PL3952872T3 (pl) | 2024-07-22 |
| HUE066941T2 (hu) | 2024-09-28 |
| EP3952872A1 (en) | 2022-02-16 |
| SI3952872T1 (sl) | 2024-07-31 |
| TW202103701A (zh) | 2021-02-01 |
| SG11202110421YA (en) | 2021-10-28 |
| BR112021019367A2 (pt) | 2021-12-07 |
| JP2022527386A (ja) | 2022-06-01 |
| HRP20240772T1 (hr) | 2024-09-13 |
| ZA202108429B (en) | 2022-09-28 |
| CN113677345A (zh) | 2021-11-19 |
| EP3952872B1 (en) | 2024-03-13 |
| RS65530B1 (sr) | 2024-06-28 |
| HU231500B1 (hu) | 2024-04-28 |
| KR20210151162A (ko) | 2021-12-13 |
| FI3952872T3 (fi) | 2024-06-12 |
| CL2021002632A1 (es) | 2022-05-06 |
| DK3952872T3 (da) | 2024-05-27 |
| GEP20237554B (en) | 2023-10-25 |
| HUP1900121A1 (hu) | 2020-10-28 |
| AU2020271363A1 (en) | 2021-11-18 |
| EA202192717A1 (ru) | 2022-01-17 |
| LT3952872T (lt) | 2024-05-27 |
| PT3952872T (pt) | 2024-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004431A (es) | Procesos novedosos. | |
| EA202091709A1 (ru) | Ингибиторы днк-пк | |
| MX2021012321A (es) | Derivados del carbamoil-ciclohexano para tratar el trastorno del espectro autista. | |
| EA201992128A1 (ru) | Конденсированные имидазопиперидиновые ингибиторы jak | |
| EA201291435A1 (ru) | Производные 5,6-дигидро-2h-[1,4]оксазин-3-иламина в качестве ингибиторов бета-секретазы (bace) | |
| EA202091708A1 (ru) | Ингибиторы днк-пк | |
| EA202091711A1 (ru) | ГЕТЕРОЦИКЛИЛАМИНОЗАМЕЩЕННЫЕ ТРИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ Rho-АССОЦИИРОВАННОЙ ПРОТЕИНКИНАЗЫ | |
| BR112017008103A2 (pt) | composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo. | |
| NZ748016A (en) | Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders | |
| MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| MX2022006807A (es) | Análogos de rapamicina y usos de estos. | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| PH12018502314A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
| NO20081014L (no) | Sammensetninger | |
| WO2017134685A3 (en) | Novel hydrazino compounds as btk inhibitors | |
| EA201000675A1 (ru) | Производные хромана как модуляторы trpv3 | |
| MX2022013396A (es) | Compuestos de tetrahidroisoquinolina como activadores de nrf2. | |
| EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
| EA202190271A1 (ru) | Замещенные триазолохиноксалиновые производные | |
| EA202091003A1 (ru) | Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3 | |
| MX2024001839A (es) | Moduladores de monoacilglicerol lipasa para uso en trastornos del espectro autista. | |
| CO2024005925A2 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| EA202092326A1 (ru) | Производные буметанида для лечения гипергидроза | |
| MX2023000198A (es) | Inhibidores de atr y usos de estos. |